Clinical trials: Patients With Heart Failure and Preserved Ejection Fraction - HFpEF
Cardiovascular Disease, Cardiometabolic Diseases
Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2 Diabetes and Cardiovascular Disease
The goal of this clinical trial is to investigate the effects of a specialized Cardio-Metabolic Clinic (CMC) in people with type 2 diabetes and established cardiovascular disease.
- Conditions
- Cardiovascular Disease, Cardiometabolic Diseases, Diabetes Type 2, Diabetes and Heart Failure
- Trial name
- NCT07878325
- Testing
- Cardio-Metabolic Clinic
- Where
- Denmark
- Volunteers
- 375 people
- Sponsor
- Odense University Hospital
Heart Failure With Normal Ejection Fraction, Obesity
Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients
The investigators hypothesize that a dietary intervention aimed at increasing unsaturated fatty acids (UFA) consumption is feasible and has the potential to improve cardiorespiratory fitness, metabolic flexibility and glucose…
- Trial name
- NCT03310099
- Testing
- Increasing daily unsaturated fatty acid consumption
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
Heart Failure With Preserved Ejection Fraction (HFpEF)
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFPEF) is a large medical problem, for which no drug or device has a recommendation in current heart failure guidelines.
- Trial name
- VIP-HF (NCT01989299)
- Testing
- ILR implantation
- Where
- 5 sites in Netherlands
- Volunteers
- 113 people
- Sponsor
- University Medical Center Groningen
HFpEF - Heart Failure With Preserved Ejection Fraction
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise.
- Trial name
- NCT05784753
- Testing
- HEART Camp, HEART Camp Connect
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
- Trial name
- NCT06616974
- Testing
- TX000045- Dose A, TX000045- Dose B
- Where
- 72 sites in United States, Armenia and 15 more
- Volunteers
- 191 people
- Sponsor
- Tectonic Therapeutic
Heart Failure With Preserved Ejection Fraction
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess…
- Trial name
- REMOD-REVERT (NCT05953831)
- Testing
- CDR132L
- Sponsor
- Cardior Pharmaceuticals GmbH
Iron Deficiency Anemia, Coronary Artery Disease
Non-Interventional Study of Ferretab® Comp. (Ferrous Fumarate + Folic Acid Prolonged-Release Capsules) Effects in Adult Patients With Iron Deficiency Anemia and Cardiovascular Disease
The goal of this observational study is to learn how well Ferretab® comp. works and how safe it is for adults with iron deficiency anemia and cardiovascular disease who are receiving treatment as part of their usual medical care.
- Conditions
- Iron Deficiency Anemia, Coronary Artery Disease, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PROMETHEUS (NCT07753031)
- Where
- 5 sites in Russia
- Volunteers
- 389 people
- Sponsor
- Alcea
Chronic Heart Failure
Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure
The aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university hospital patients .
- Trial name
- NCT05090202
- Testing
- hbA1C
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
HFpEF
Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction
What is HFpEF? In heart failure with preserved ejection fraction (HFpEF), the heart pumps well but struggles to relax and fill with blood between beats.
- Trial name
- APAVE (NCT07270536)
- Testing
- Accelerated pacing with AV-delay optimization during rest and light intensity cycling
- Where
- 2 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Heart Failure
Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)
The major goal of this proposal is to characterize the ability of epicatechin which a component of dark chocolate to improve the 1. structural and functional features of skeletal muscle (SkM) 2.
- Trial name
- HFPEF (NCT02068040)
- Testing
- CocoaVia
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Heart failure is the most common cause of death of patients on chronic hemodialysis treatment, and to date there is no effective therapy for the treatment of this comorbidity in this group of patients.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan
- Trial name
- NCT07417215
- Testing
- Sacubitril / Valsartan
- Where
- Bosnia and Herzegovina
- Volunteers
- 52 people
- Sponsor
- University Clinical Hospital Mostar
Atrial Fibrillation, SGLT2 Inhibitor
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown.
- Conditions
- Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
- Trial name
- NCT07776054
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Heart Failure, Inflammation
Colchicine in HFpEF
Heart failure is a growing epidemic that affects up to 500,000 individuals in Canada, with 50,000 new cases being diagnosed each year. Half of these will have HF with preserved ejection fraction (HFpEF).
- Conditions
- Heart Failure, Inflammation, Colchicine
- Trial name
- COLpEF (NCT04857931)
- Testing
- Colchicine
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Montreal Heart Institute
Heart Failure With Preserved Ejection Fraction
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
- Trial name
- HFpEF-BB (NCT05174351)
- Testing
- beta blocker discontinuation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UConn Health
Heart Failure With Preserved Ejection Fraction
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
Beta blockers have been used to reduce the mortality and heart failure rehospitalization in heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA, ivabradine and ARNI.
- Trial name
- NCT03948685
- Testing
- Carvedilol SR
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University